Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

QVA149; NVA237; tiotropium; Salbutamol/albuterol

A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Номер протоколаCQVA149A2304
ФазаФаза III
Участников по плану — во всех странах исследования2 224
Сроки01.04.2010 — 01.07.2012
Начало: 1 апреля 2010Окончание: 1 июля 2012
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01120691/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 40 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 2224 чел. во всех странах исследования.
  • Плановая дата окончания (07.2012) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 40 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • Стадияместно-распространённая (III)

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 37

Критерии включения

  • Male or female adults aged ≥40 years, who had signed an informed consent form prior to initiation of any study-related procedure.
  • Patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD (Stage III or IV) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
  • Current or ex-smokers with a smoking history of at least 10 pack years (Ten pack-years were defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years).
  • Patients with a post-bronchodilator Forced Expiratory Volume in one second ( FEV1) <50% of the predicted normal value, and post-bronchodilator FEV1/ Forced Vital Capacity (FVC) <0.70 at Visit 2 (day -14). (Post refers to 1 h after sequential inhalation of 84 µg (or equivalent dose) of ipratropium bromide and 400 µg of salbutamol).
  • A documented history of at least 1 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticosteroids and/or antibiotics.

Критерии невключения

  • Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).
  • Women of child-bearing potential
  • Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for chronic hypoxemia.
  • Patients who had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to visit 1 or between visit 1 (Day -21) and Visit 3 (Day 1).
  • Patients who developed a COPD exacerbation during a period between visit 1 and 3 were ineligible but were permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation.
  • Patients who had a respiratory tract infection within 4 weeks prior to visit 1 (Day -21)
  • Patients who developed an upper or lower respiratory tract infection during the screening period (up to visit 3 (Day 1) were not eligible, but were permitted to be re-screened 4 weeks after the resolution of the respiratory tract infection
  • Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless confirmed by chest x-ray to be no longer active), clinically significant bronchiectasis, sarcoidosis, interstitial lung disorder or pulmonary hypertension.
  • Patients with lung lobectomy, or lung volume reduction or lung transplantation.
  • Patients who, in the judgment of the investigator, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to):
  • Unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding chronic stable Atrial Fibrillation (AF). Patients with such events not considered clinically significant by the investigator may be considered for inclusion in the study
  • history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
  • uncontrolled hypo- or hyperthyroidism, hypokalemia or hyper adrenergic state
  • narrow-angle glaucoma
  • Symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention. (Patients with a Transurethral Resection of Prostate (TURP) were excluded from the study. Patients who underwent full re-section of the prostate could be considered for the study, as well as patients who were asymptomatic and stable on pharmacological treatment for the condition).
  • any condition which might have compromised patient safety or compliance, interfered with evaluation, or precluded completion of the study
  • Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm3 (at visit 2), or onset of symptoms prior to 40 years. Patients without asthma were excluded if their eosinophil count was >600/mm3 at visit 2.
  • Patients with allergic rhinitis who used H1 antagonists or intranasal corticosteroids intermittently (treatment with a constant dose was permitted).
  • Patients with eczema (atopic), known high immunoglobulin E (IgE) levels or a known positive skin prick test in the last 5 years.
  • Patients with known history and diagnosis of alpha-1 antitrypsin deficiency.
  • Patients who were participating in the active phase of a supervised pulmonary rehabilitation program.
  • Patients with Type I or uncontrolled Type II diabetes.
  • Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs or drugs of a similar class or any component thereof:
  • anticholinergic agents
  • long and short acting beta-2 agonists
  • sympathomimetic amines.
  • Patients with a history of long QT syndrome or whose corrected QT interval (QTc) measured at visit 2 (Day -14) (Fridericia method) was prolonged (>450 ms for males and females) as confirmed by the central ECG assessor.
  • Patients with a clinically significant abnormality on the screening or baseline ECG who in the judgment of the investigator would be at potential risk if enrolled into the study. (These patients could not be re-screened).
  • Patients who needed treatments for COPD and allied conditions after the start of the study (visit 1)
  • Patients who needed treatments for COPD and allied conditions (e.g. allergic rhinitis) unless they had been stabilized
  • Patients taking other prohibited medications
  • Patients unable to use a dry powder inhaler (e.g. single dose dry powder inhaler (SDDPI), HandiHaler® device, or pressurized Metered Dose Inhaler (MDI) (rescue medication).
  • Patients unable to use an electronic patient diary.
  • Patients who were, in the opinion of the investigator known to be unreliable or non-compliant.
  • Patients who used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of visit 1 (day -21), whichever was longer.
  • Patients who had live attenuated vaccination within 30 days prior to the screening visit or during the run-in period. Inactivated influenza vaccination, pneumococcal vaccination or any other inactivated vaccine was acceptable provided it was not administered within 48 hours prior to screening and randomization visits.
  • No additional exclusions were applied by the investigator, in order to ensure that the study population was representative of all eligible patients.

Источник: ClinicalTrials.gov, NCT01120691 · запись обновлена в реестре 2 декабря 2013.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)2 224
Что измеряют — первичные конечные точки (1), вторичных — 12
  • Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period. — 64 weeks

Цель исследования

This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01120691 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.